Quest not over

Medivir AB (SSE:MVIR B) gained 12% last week following strong SVR12 data from three Phase III HCV trials of its simeprevir plus interferon and ribavirin, but the more significant value-creating event for the protease inhibitor will come next year in the form of results from IFN-free combination trials.